Rigel Pharmaceuticals Inc. (New) earnings per share and revenue
On Nov 04, 2025, RIGL reported earnings of 1.46 USD per share (EPS) for Q3 25, beating the estimate of 0.87 USD, resulting in a 67.47% surprise. Revenue reached 69.46 million, compared to an expected 63.12 million, with a 10.05% difference. The market reacted with a +33.37% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 7 analysts forecast an EPS of 1.18 USD, with revenue projected to reach 69.28 million USD, implying an decrease of -19.18% EPS, and decrease of -0.26% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Takeda Pharmaceutical Company Limited - ADR
Report Date
Jan 30, 2026 For Q3 26
Estimate
$34.44
Actual
$65.64
Surprise
+90.61%
FAQ
What were Rigel Pharmaceuticals Inc. (New)'s earnings and revenue for the latest quarter Q3 2025?
For Q3 2025, Rigel Pharmaceuticals Inc. (New) reported EPS of $1.46, beating estimates by 67.47%, and revenue of $69.46M, 10.05% above expectations.
How did the market react to Rigel Pharmaceuticals Inc. (New)'s Q3 2025 earnings?
The stock price moved up 33.37%, changed from $28.38 before the earnings release to $37.85 the day after.
When is Rigel Pharmaceuticals Inc. (New) expected to report next?
The next earning report is scheduled for Mar 02, 2026.
What are the forecasts for Rigel Pharmaceuticals Inc. (New)'s next earnings report?
Based on 7
analysts, Rigel Pharmaceuticals Inc. (New) is expected to report EPS of $1.18 and revenue of $69.28M for Q4 2025.